Blanket Purchase Agreement 36F79718D0355-36E79722A0026
Award Date
9/1/22
Last Date to Order
8/31/25
Federal Agency
National Acquisition Center
Awardee
Alexion Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract, specifically the Pharmaceuticals and Drugs (FSS-61-IB) schedule, to Alexion Pharmaceuticals Inc. (Alexion). The contract has a ceiling value of $47,000,000 and a period of performance from April 1, 2018 through September 30, 2025. Under this contract, Alexion provides pharmaceutical products, including the drug Strensiq, to various VA healthcare facilities and networks nationwide. The VA has placed...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Catalyst Pharmaceuticals, Inc. The BPA, valued at $5,500,000, is placed against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of July 25, 2026. The primary purpose of this BPA is to enable the procurement of the pharmaceutical product Firdapse (amifampridine), an FDA-approved...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021. The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, was awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The $151,685 BPA has a potential value over $3 million and will run through October 2024, facilitating the VA's procurement of the drug Palynziq (pegvaliase-pqpz) to treat phenylketonuria in adult patients. Under this BPA, the VA has issued a $117,376.50 firm...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, to provide critical medications for the treatment of rare diseases such as pulmonary arterial hypertension. The $118.5 million BPA covers the period from August 2024 to August 2025 and allows the VA, Federal Bureau of Prisons, and other federal agencies to procure specialized drug therapies like...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025. The VA Greater Los Angeles Healthcare System...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract to BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract has a ceiling value of $3,139,060 and runs through June 2026. Under this FSS contract, the VA has issued several delivery orders and a $151,685 Blanket Purchase Agreement (BPA) to procure the drug Palynziq (pegvaliase-pqpz) from BioMarin. The delivered Palynziq is...